Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allied BiotechROCO:1780 77 EV-to-EBITDA is 7.28 as of Sep. 16, 2026, which is 36% below its 10-year median of 11.38. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$22.15 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 744 Drug Manufacturers companies, Allied Biotech ranks better than 73.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Allied Biotech's enterprise value is NT$2,240.1 Mil.
Allied Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$307.6 Mil. Therefore, Allied Biotech's EV-to-EBITDA for today is 7.28.
The historical rank and industry rank for Allied Biotech's EV-to-EBITDA or its related term are showing as below:
ROCO:1780'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7 Med: 11.38 Max: 60.27
Current: 7.28
During the past 13 years, the highest EV-to-EBITDA of Allied Biotech was 60.27. The lowest was 5.70. And the median was 11.38.
ROCO:1780's EV-to-EBITDA is ranked better than 73.52% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.245
vs ROCO:1780: 7.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allied Biotech's PE Ratio (TTM) for today is calculated as:
Allied Biotech's share price for today is NT$24.80.
Allied Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.867.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Allied Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Allied Biotech's EV-to-EBITDA falls into.
Allied Biotech's current Enterprise Value is NT$2,240.1 Mil.
Allied Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$307.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allied Biotech (ROCO:1780) has a EV-to-EBITDA of 7.28 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Allied Biotech. This is 36% below median its historical median of 11.38. Over the past decade, Allied Biotech's EV-to-EBITDA has ranged from 5.70 to 60.27. According to the industry distribution chart, Allied Biotech ranks #197 out of 744 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Allied Biotech's EV-to-EBITDA too high?
Allied Biotech's current EV-to-EBITDA of 7.28 is 36% below median its 10-year median of 11.38. Over the past 10 years, this metric has ranged from a low of 5.70 to a high of 60.27. The Drug Manufacturers industry median EV-to-EBITDA is 12.25. Allied Biotech's value of 7.28 is 40.5% below this industry median. Based on the distribution chart, Allied Biotech ranks #197 out of 744 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #197 out of 744 companies for EV-to-EBITDA. This puts Allied Biotech in the upper half of its industry. The industry median EV-to-EBITDA is 12.25. Allied Biotech's value of 7.28 is 40.5% below this benchmark. Historically, Allied Biotech's own EV-to-EBITDA has ranged from 5.70 to 60.27 over the past decade. While the company's 10-year median is 11.38 vs. the industry median of 12.25, Allied Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.25, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allied Biotech's current EV-to-EBITDA of 7.28 is 40.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Allied Biotech. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current EV-to-EBITDA is 7.28, which is 36% below median its own 10-year median of 11.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.15, compared to a current price of NT$24.80 — trading 12% above its estimated fair value. The current EV-to-EBITDA is 7.28, which is 36% below median its 10-year median of 11.38 and 40.5% below the Drug Manufacturers industry median of 12.25. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current EV-to-EBITDA is 7.28 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$24.80 is trading 12% above its estimated GF Value™ of NT$22.15.
GuruFocus considers Allied Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:1780:
EV-to-EBITDA: 7.28 (36% below median its 10-year median of 11.38)
GF Value™: NT$22.15 vs. price of NT$24.80 (12% above fair value)
Industry Position: 40.5% below the Drug Manufacturers median (#197 of 744)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
